Kancera presents the company and its projects at Cambridge Innovation Center in Boston (MA) USA on Friday April 27th, 2012. The overall topic of the seminar is "Lead Generation and Structure-Based Drug Design in Cancer Research".
Read MoreKancera announced today that American Society of Clinical Oncology has selected Kancera's ROR project for presentation at this year's major conference in Chicago on June 1-5, 2012.The scientific results will be presented by Professor Håkan Mellstedt in a paper...
Read MoreKancera today announced that its ROR inhibitor show effect in an advanced and challenging human pancreatic cancer model. In the model, the Kancera compounds show superior efficacy compared to gemcitabine, today's most commonly used treatment for pancreatic cancer. The...
Read MoreOn February 8th Kancera's CEO, Dr. Thomas Olin, presented the company and new data in its ROR inhibitor project on the "6th Swiss-Scandinavian Bio-Business Seminar" in Zurich. In his presentation Dr. Olin described how Kancera, in collaboration with...
Read MoreKancera reports that the company has registered a patent application (EP12153357) for new substances that prevents the ability of the cancer to survive. The new patent is based on Kancera's ROR technology directed against both leukemia and solid tumors....
Read MoreToday Kanceras Chief Scientific Officer, Professor Lars Ährlund-Richter, presents the company and its PFKFB3 inhibitor project at the World Cancer Metabolism Summit in Washington. The meeting brings together world experts in oncology from both the pharmaceutical industry and academia....
Read MoreiNovacia AB, the provider of small molecule drug discovery services, today announced that it has entered into a high-throughput screening collaboration with Agios Pharmaceuticals, Cambridge (MA), USA.
Read MoreKancera report that the Company has registered a patent application for novel compounds targeting the energy metabolism of cancer. The new patent application covers a strategy to facilitate the uptake of substances in cancer cells. These synthetic molecules weaken...
Read MoreIn an ongoing and open collaboration between iNovacia AB, GE Healthcare, Sweden and scientists at the Department of Medical Biochemistry and Biophysics (MBB) at Karolinska Institutet, the surface plasmon resonance and nuclear magnetic resonance techniques have been cross-validated as...
Read MoreKancera co-founder and scientific adviser Professor Håkan Mellstedt has demonstrated a sustained presence of Kancera's ROR1 target over time in patients with non-progressive disease and also a significant increase of this putative tumor target in patients with progressive stages...
Read More